Tortugas Neuroscience, a privately held clinical-stage biotechnology company based in Framingham, Massachusetts, announced on October 12, 2026, that its investigational oral schizophrenia treatment obuprazine (TRTL-107) met the primary endpoint across all three dose groups in a randomized Phase 2b clinical trial involving 363 adults in China. The strongest numerical result came from the 1.5 mg to 3.0 mg dose group, which achieved a 16.7-point placebo-adjusted improvement in Positive and Negative Syndrome Scale (PANSS) total score after 42 days, with statistical significance at p<0.0001.
The findings were presented at the 2026 European College of Neuropsychopharmacology Congress in Munich, Germany, on October 10 by researchers working with Hansoh Pharmaceutical Group Co., Ltd. (Hong Kong Stock Exchange: 3692), which conducted the study and originally developed the molecule. All three investigated dose groups demonstrated statistically significant improvements over placebo, while secondary assessments indicated reductions in positive and negative schizophrenia symptoms and a PANSS-derived cognitive symptom factor. Tortugas also reported adverse-event discontinuation rates of approximately 2.1% among obuprazine recipients compared with 2.5% in the placebo group.
The announcement provides meaningful clinical validation for Tortugas, which launched in April 2026 with $106 million in seed and Series A financing and an externally licensed central nervous system pipeline. Obuprazine is its most advanced candidate, with global commercial development rights held by Tortugas outside Greater China. The company intends to submit a United States Investigational New Drug application, an initial regulatory step toward conducting domestic clinical investigations rather than an application for marketing approval.
The efficacy findings are encouraging, particularly because the trial included an established antipsychotic, aripiprazole, as an active reference. However, the reported superiority testing focused on comparisons with placebo, and the company’s statement that obuprazine performed numerically better than aripiprazole does not establish statistically confirmed superiority over that medicine. The next development phase must also determine whether the short-term symptom improvements can be sustained without unacceptable metabolic, neurological or other treatment-related adverse effects.
How significant is obuprazine’s 16.7-point PANSS improvement in the Phase 2b schizophrenia trial?
The Phase 2b investigation enrolled 363 adults with acute schizophrenia across 24 clinical centers in China. Participants were randomly assigned to five groups receiving obuprazine at 1.5 mg to 3.0 mg, 4.5 mg to 6.0 mg or 6.0 mg to 9.0 mg, or receiving aripiprazole or placebo. The study was double-blind, with treatment continuing for six weeks and the primary efficacy assessment conducted on Day 42.
The PANSS is a clinician-rated instrument containing 30 items measuring positive symptoms, negative symptoms and general psychopathology. Total scores range from 30 to 210, with higher values indicating greater symptom severity. Changes in PANSS are widely used in antipsychotic clinical trials because they provide a standardized measure of symptom improvement, although changes in the total score do not necessarily establish improved daily functioning or long-term recovery.
Patients receiving the lowest obuprazine dose range achieved a least-squares mean reduction of 28.6 points from baseline, compared with an 11.9-point reduction in the placebo group. The resulting placebo-adjusted difference was negative 16.7 points, with a 95% confidence interval extending from negative 22.5 to negative 10.9 points. The difference was statistically significant, supporting the company’s conclusion that this dose met the trial’s primary endpoint.
The middle-dose group achieved a placebo-adjusted reduction of 13.2 points, with a 95% confidence interval of negative 18.9 to negative 7.4 points. The highest-dose group produced a 14.7-point improvement versus placebo, with a confidence interval of negative 20.5 to negative 8.8 points. All three dose comparisons achieved reported p-values below 0.0001.
The consistency across doses strengthens evidence that obuprazine has antipsychotic activity in the studied population. However, the largest numerical improvement occurred in the lowest dose group rather than the highest, indicating that the observed efficacy was not simply greater with increasing administered dose. That pattern makes dose selection particularly important for future development because the optimal regimen must balance clinical activity, tolerability and the pharmacological exposure needed for sustained treatment.
Why does obuprazine’s numerical advantage over aripiprazole require careful interpretation?
Aripiprazole was included as an active reference treatment, giving the trial an additional benchmark against a well-established antipsychotic. Hansoh reported a placebo-adjusted PANSS improvement of 12.1 points for aripiprazole at Day 42, compared with 16.7, 13.2 and 14.7 points for the three obuprazine groups. The lowest-dose obuprazine group therefore showed a numerically larger improvement than the active reference.
However, the treatment allocation was not balanced equally across all five groups. Approximately 80 patients were assigned to each obuprazine group, while 40 received aripiprazole and 81 received placebo. The smaller active-reference group limits the precision of comparative estimates, particularly when evaluating potential differences between the experimental medicine and the established treatment.
More importantly, the reported primary statistical analysis evaluated each obuprazine dose against placebo. Tortugas and Hansoh have not disclosed a prespecified, statistically significant superiority result for obuprazine versus aripiprazole. The observed numerical differences are therefore hypothesis-generating rather than evidence that obuprazine is clinically more effective.
The distinction will become commercially important if Tortugas advances the programme into larger trials. Aripiprazole is widely prescribed and available in multiple formulations, creating a substantial clinical evidence base and an established low-cost generic treatment option. Demonstrating symptom improvement against placebo is necessary for development, but commercial differentiation may eventually require convincing evidence regarding treatment persistence, adverse effects or patient populations inadequately served by existing medicines.
What do the positive, negative and cognitive symptom findings reveal about obuprazine’s potential?
One of the more interesting aspects of the Phase 2b disclosure is the reported improvement across several schizophrenia symptom domains. Positive symptoms include experiences such as hallucinations and delusions, while negative symptoms may involve reduced motivation, diminished emotional expression and social withdrawal. Cognitive difficulties can affect attention, memory and executive functioning, contributing to disability even when overt psychotic symptoms are controlled.
Tortugas reported that all three obuprazine dose groups demonstrated statistically significant improvements versus placebo on the PANSS positive and negative symptom subscales at Day 42. The 1.5 mg to 3.0 mg group showed placebo-adjusted improvements of 5.3 points on the positive symptom subscale and 4.4 points on the negative symptom subscale, both with p-values below 0.0001. These findings provide evidence of broader measured symptom improvement within the six-week trial.
The company also reported statistically significant improvements in the PANSS Marder cognitive factor. This is a useful measure of cognitive-related symptom characteristics derived from items within the broader PANSS assessment, but it is not equivalent to a dedicated neuropsychological battery measuring memory, attention or executive performance. Consequently, the results should not be interpreted as proof that obuprazine improves cognitive functioning in everyday life.
Negative symptom findings require similar care because improvements may occur alongside reductions in acute positive symptoms. Patients experiencing fewer hallucinations, less agitation or reduced disorganization can show changes in broader symptom assessments without necessarily demonstrating a direct therapeutic effect on persistent primary negative symptoms. A study specifically designed to evaluate enduring negative symptoms would provide stronger evidence of that potential benefit.
The trial’s eligibility criteria also matter. Participants were experiencing acute schizophrenia symptoms, with baseline PANSS total scores between 80 and 120 and clinically significant positive symptoms. The study excluded treatment-resistant schizophrenia, meaning the results cannot establish efficacy among patients who have failed adequate trials of established antipsychotics.
The reported breadth of improvement nevertheless supports further investigation of obuprazine as a treatment for acute schizophrenia. If subsequent trials demonstrate consistent effects on positive and negative symptoms while confirming functional improvements, the medicine could develop a more differentiated clinical profile. For now, the strongest conclusion remains that all three doses improved measured symptoms relative to placebo during the controlled six-week study.
How strong is the evidence that obuprazine begins improving schizophrenia symptoms within 14 days?
Tortugas highlighted early treatment response as another potentially distinguishing feature of obuprazine. According to the company, the lowest and middle dose groups showed higher proportions of patients achieving at least a 50% reduction in PANSS total score compared with placebo and aripiprazole as early as Day 14. This suggests that substantial symptom improvement was observed in some participants relatively early during treatment.
However, the public announcement did not provide the actual Day 14 responder percentages, confidence intervals or statistical comparisons supporting the early-response claim. Without those figures, it is not possible to determine the absolute difference between treatment groups or the precision of the estimated advantage. The finding is encouraging, but its strength cannot be independently assessed from the headline description alone.
There is also an important distinction between the reported early-response analysis and the trial’s registered responder endpoint. The clinical trial record identifies a 40% reduction in PANSS total score at Day 42 as a secondary measure, whereas the company’s early-response discussion uses a threshold of at least 50% at Day 14. These are different measures and should not be treated as interchangeable or as evidence that the same statistical analysis was prespecified.
The potential commercial relevance of rapid response is understandable. Patients experiencing acute schizophrenia exacerbations may require hospitalization, close observation and treatment adjustments before symptoms stabilize. A medicine producing reliable symptom improvement relatively early could be clinically useful, but a six-week inpatient study does not establish reduced hospitalization duration, fewer emergency interventions or better long-term adherence.
The next studies will need to determine whether early differences persist across a broader population and whether they translate into meaningful clinical consequences. Sustained symptom control, tolerability and treatment continuation are particularly important because schizophrenia generally requires ongoing management beyond the acute treatment period.
What does the Phase 2b safety profile establish about obuprazine’s tolerability?
Tortugas described the six-week safety findings as favorable, reporting adverse-event discontinuation rates of approximately 2.1% across obuprazine-treated participants compared with 2.5% in the placebo group. Hansoh separately indicated that most treatment-emergent adverse events were mild or moderate in severity and that no new significant safety concerns were identified. These observations suggest that discontinuation due to adverse events was relatively uncommon during the controlled treatment period.
However, discontinuation rates provide only one measure of tolerability. The companies have not disclosed a comprehensive adverse-event table covering the incidence of extrapyramidal symptoms, akathisia, weight gain, metabolic changes, sedation, prolactin abnormalities or cardiovascular findings. Such information will be essential for assessing whether obuprazine offers a clinically useful tolerability advantage over established antipsychotic medicines.
The distinction is particularly important because dopamine receptor modulation is associated with a range of pharmacological effects beyond symptom reduction. Depending on a medicine’s receptor activity and exposure, treatment can influence movement, restlessness, endocrine function and other physiological processes. Obuprazine’s specific safety characteristics must be established through clinical evidence rather than inferred from its molecular mechanism.
The six-week duration also limits conclusions about adverse effects that may emerge with longer treatment. Weight changes, metabolic complications and movement disorders can become particularly relevant during sustained antipsychotic use. A treatment that demonstrates acceptable short-term tolerability may still require adjustments to dosing or monitoring during maintenance therapy.
The low discontinuation rate remains a positive observation, particularly when considered alongside the magnitude of the reported efficacy response. Nevertheless, the absence of detailed adverse-event frequencies prevents a definitive comparison with aripiprazole or other antipsychotics. Longer exposure and a more complete safety dataset will be necessary before the medicine’s benefit-risk profile can be adequately characterized.
How does obuprazine’s dopamine and serotonin receptor activity differ from newer schizophrenia treatments?
Obuprazine is an oral small molecule acting through several dopamine and serotonin receptors involved in neurotransmission. The compound is described as a partial agonist of dopamine D2 and D3 receptors, an antagonist of serotonin 5-HT2A receptors and a partial agonist of serotonin 5-HT1A receptors. This combination is intended to modulate pathways associated with psychotic symptoms while potentially influencing other dimensions of schizophrenia.
Partial agonists can produce different receptor effects depending on the surrounding neurotransmitter environment and their intrinsic activity. In schizophrenia treatment, dopamine D2 partial agonism is an established pharmacological strategy, used by medicines including aripiprazole and other approved antipsychotics. Obuprazine therefore builds on a clinically validated therapeutic approach rather than introducing an entirely new biological target.
Its additional receptor characteristics may offer opportunities for differentiation, but the magnitude of any clinical advantage cannot be predicted solely from receptor binding and functional activity. Several antipsychotics already interact with multiple dopamine and serotonin receptors. The relevant question is whether obuprazine’s specific pharmacological profile produces superior efficacy, tolerability or treatment persistence in adequately controlled trials.
The broader schizophrenia market has also become more competitive following the September 2024 United States Food and Drug Administration approval of Bristol Myers Squibb Company’s Cobenfy, a combination of xanomeline and trospium chloride. Cobenfy uses muscarinic receptor-based pharmacology rather than relying on direct dopamine receptor antagonism or partial agonism as its principal therapeutic mechanism. Its approval introduced another treatment strategy into a field historically dominated by dopamine-modulating medicines.
This development changes the competitive context for obuprazine. A future medicine cannot rely solely on positive placebo-controlled results to establish a compelling commercial proposition, particularly when prescribers already have access to multiple oral and long-acting injectable antipsychotics. Tortugas will need to demonstrate where its candidate offers meaningful clinical value within an increasingly diverse treatment landscape.
Why is the Hansoh Pharmaceutical Group licensing arrangement important for Tortugas Neuroscience?
Tortugas acquired rights to obuprazine through its licensing relationship with Jiangsu Hansoh Pharmaceutical Group, part of the publicly listed Hansoh Pharmaceutical Group. The American company holds global commercial development rights outside Greater China, while Hansoh retains responsibility for its existing regional development interests. The completed Phase 2b study therefore provides clinical evidence generated by the Chinese partner that Tortugas can use when planning development in other markets.
This model allows Tortugas to build its pipeline around assets that have already undergone human clinical testing. Rather than beginning with early drug discovery, the company is seeking to use established clinical programmes and further development to identify commercially differentiated treatments. Obuprazine represents the most advanced example of that strategy within its current portfolio.
Tortugas launched in April 2026 with $106 million in combined seed and Series A financing. Its founding investors include Cure Ventures, The Column Group and AN Venture Partners, providing funding for a portfolio that includes several licensed central nervous system assets. The company has not disclosed a revised valuation or additional financing specifically attributable to the October schizophrenia results.
Its development pipeline also includes an investigational GABA receptor positive allosteric modulator licensed from Hansoh for tinnitus, alongside programmes originating from Eisai Co., Ltd. involving a GABA transporter 1 inhibitor for focal epilepsy and a phosphodiesterase 9 inhibitor for reversible encephalopathies. These assets provide exposure to different neurological and neuropsychiatric indications, although positive obuprazine results do not establish the efficacy of the other candidates.
For Hansoh, the trial success provides additional validation of its internally developed central nervous system portfolio and a potential foundation for later-stage development in China. For Tortugas, the immediate economic significance is different because obuprazine remains investigational and has not generated approved-product sales. The financial terms of the individual licensing arrangement have not been sufficiently disclosed to calculate the future economics of obuprazine commercialization.
What regulatory and clinical milestones must Tortugas complete before obuprazine can advance in the United States?
The next declared step is submission of a United States Investigational New Drug application for TRTL-107. An effective IND would allow the company to conduct clinical investigations under applicable regulatory requirements, but it would not constitute approval of obuprazine for schizophrenia treatment. Tortugas has not announced that the FDA has accepted a marketing application or authorized the drug for commercial use.
The company will need to assess whether the existing Chinese development package adequately supports the proposed United States clinical programme. This may involve clinical pharmacology, manufacturing documentation, dose justification, nonclinical information and safety monitoring plans. The FDA may also require additional studies or modifications to the proposed development strategy.
Hansoh has indicated that the positive Phase 2b results support progression toward Phase 3 development. However, the companies have not disclosed a finalized global Phase 3 protocol, specific enrollment target, primary endpoint or confirmed initiation schedule. The next programme should therefore be described as planned rather than already underway.
Dose selection will be particularly important because the lowest investigated dose range produced the strongest numerical PANSS improvement. Further assessment of exposure-response relationships, individual treatment responses and adverse effects could help determine whether one dose or a flexible dosing strategy offers the most appropriate balance. The company’s current claim of potential dosing flexibility requires confirmation through additional evidence.
A larger trial will also need to address whether the results extend beyond adults hospitalized with acute schizophrenia in China. The Phase 2b study excluded treatment-resistant patients and several groups with potentially complicating clinical conditions, which limits the generalizability of its findings. Broader international trials could provide more information about consistency across healthcare settings and patient characteristics.
The planned peer-reviewed publication of detailed Phase 2b results is another meaningful milestone. Full reporting could clarify the statistical analysis, responder definitions, missing data, dose relationships and adverse-event profile. Such detail will allow clinicians and researchers to assess the findings more completely than is possible from the current conference and company disclosures.
Obuprazine has delivered a positive and numerically substantial Phase 2b schizophrenia result, with all three dose groups meeting the primary endpoint and the strongest treatment group achieving a 16.7-point placebo-adjusted PANSS improvement. The study also provides encouraging preliminary evidence of broader symptom effects and early response, but claims of superiority over aripiprazole, improved cognitive functioning or better long-term tolerability remain unproven.
For Tortugas Neuroscience, the immediate achievement is a stronger clinical foundation for its lead asset and a clearer rationale for pursuing United States development. The next decisive evidence will come from confirming the optimal dose, characterizing long-term adverse effects and reproducing the treatment benefit in larger, appropriately designed studies. Those findings will determine whether obuprazine can progress from a promising licensed schizophrenia candidate into a differentiated antipsychotic treatment with a viable regulatory and commercial future.
